|RAAS Marker||n||Events||Median Split∗||Log2 Transformation|
|HR (95% CI)||p Value||HR (95% CI)||p Value|
|PRA||427||134||1.28 (0.91–1.82)||0.16||1.05 (0.98–1.13)†||0.18|
|Aldosterone||427||134||1.39 (0.96–2.01)||0.080||1.13 (0.99–1.28)†||0.069|
|PRA change (HR for 10-U increase)||363||117||0.99 (0.92–1.06)‡||0.70|
|Aldosterone change (HR for 100-U increase)||372||119||1.00 (0.94–1.06)‡||0.90|
Abbreviations as in Table 2.
↵∗ Hazard ratio (HR) for RAAS activation measure ≥ median versus < median (PRA median = 5 ng/ml/h; aldosterone median = 210 pg/ml) from proportional hazards regression model adjusted for trial, and baseline ACE-I/ARB and aldosterone antagonist use.
↵† Hazard ratio for doubling of RAAS activation measurement from proportional hazards regression model adjusted for trial and baseline ACE-I/ARB and aldosterone antagonist use.
↵‡ Proportional hazards regression models for change in RAAS activation from baseline to 72 h or 96 h, adjusted for trial, baseline RAAS activation, and ACE-I/ARB and aldosterone antagonist use.